Please assess the completion status of the following clinical trial:

Trial Title: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CD20-positive PTLD with or without EBV association, confirmed after biopsy or resection of tumor~* Measurable disease of \> 2 cm in diameter and/or bone marrow involvement~* Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or a combination of the organ transplantations mentioned~* ECOG ≤ 2~* Clinically insufficient response to an upfront reduction of immunosuppression with or without antiviral therapy~* Age at least 18 years~* Not legally incapacitated~* Written informed consent from the trial subject has been obtained~Exclusion Criteria:~* Complete surgical extirpation of the tumor or irradiation of residual tumor masses~* Upfront treatment with rituximab or chemotherapy~* Known allergic reactions against foreign proteins~* Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol~* Meningeal and CNS involvement~* Known to be HIV-positive~* Pregnant women and nursing mothers~* Failure to use highly-effective contraceptive methods~* Persons held in an institution by legal or official order~* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator~* Life expectancy less than 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low-risk (Type: EXPERIMENTAL): All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
- High risk (Type: EXPERIMENTAL): All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
- Very high-risk (Type: EXPERIMENTAL): All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.

Based on this trial design, predict the completion outcome and termination type (if applicable).